



National
Comprehensive
Cancer
Network®

NCCN Clinical Practice Guidelines in Oncology™

Adult Cancer Pain

V.1.2009

Continue

www.nccn.org

NCCN Adult Cancer Pain Panel Members

* Robert Swarm, MD/Chair ϕ \pounds
Siteman Cancer Center at Barnes-Jewish
Hospital and Washington University School
of Medicine

Amy Pickar Abernethy, MD \dagger
Duke Comprehensive Cancer Center

Doralina L. Anghelescu, MD ϕ
St. Jude Children's Research
Hospital/University of Tennessee Cancer
Institute

Costantino Benedetti, MD ϕ \pounds
Arthur G. James Cancer Hospital & Richard
J. Solove Research Institute at The Ohio
State University

Craig D. Blinderman, MD, MA ρ \pounds
Massachusetts General Hospital Cancer
Center

Barry Boston, MD \pounds \dagger
St. Jude Children's Hospital/University of
Tennessee Cancer Institute

Charles Cleeland, PhD θ
The University of Texas M. D. Anderson
Cancer Center

Nessa Coyle, PhD, NP \pounds $\#$
Memorial Sloan-Kettering Cancer Center

Oscar A. deLeon-Casasola, MD ϕ \pounds
Roswell Park Cancer Institute

June G. Eilers, RN, PhD $\#$
UNMC Eppley Cancer Center at The
Nebraska Medical Center

Betty Ferrell, RN, PhD \pounds $\#$
City of Hope Comprehensive Cancer Center

Nora A. Janjan, MD, MPSA, MBA \S
The University of Texas M. D. Anderson
Cancer Center

Michael H. Levy, MD, PhD \pounds \dagger
Fox Chase Cancer Center

Maureen Lynch, RN, NP \pounds $\#$
Dana-Farber/Brigham and Women's Cancer
Center

Gustavo S. Montana, MD \S
Duke Comprehensive Cancer Center

Barbara A. Murphy, MD \pounds \dagger
Vanderbilt-Ingram Cancer Center

Suzanne Nesbit, PharmD, BCPS Σ
The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins

Linda Oakes, RN, MSN $\#$
St. Jude Children's Research Hospital/
University of Tennessee Cancer Institute

Eugenie A. Obbens, MD, PhD \pounds Ψ
Memorial Sloan-Kettering Cancer Center

Judy Paice, PhD, RN \pounds $\#$
Robert H. Lurie Comprehensive Cancer
Center of Northwestern University

Karen L. Syrjala, PhD θ
Fred Hutchinson Cancer Research
Center/Seattle Cancer Care Alliance

Susan Urba, MD \pounds \dagger
University of Michigan Comprehensive
Cancer Center

Sharon M. Weinstein, MD \pounds Ψ
Huntsman Cancer Institute at the
University of Utah

[NCCN Guidelines Panel Disclosures](#)**Continue**

ϕ Anesthesiology
 \pounds Supportive Care including Palliative, Pain
management, Pastoral care and Oncology social work
 \dagger Medical oncology
 ρ Internal medicine
 θ Psychiatry, psychology, including health behavior
 $\#$ Nursing
 \S Radiotherapy/Radiation oncology
 Σ Pharmacology
 Ψ Neurology/neuro-oncology
* Writing Committee member

Table of Contents

[NCCN Adult Cancer Pain Panel Members](#)

[Summary of Guidelines Updates](#)

[Universal Screening and Assessment \(PAIN-1\)](#)

[Management of Pain in Patients Not Taking Opioids \(PAIN-2\)](#)

[Response to Severe, Moderate, or Increased Pain with Short-Acting Opioids \(PAIN-3\)](#)

[Subsequent Treatment of Pain \(PAIN-4\)](#)
[Ongoing Care \(PAIN-5\)](#)

[Pain Intensity Rating \(PAIN-A\)](#)

[Procedure-Related Pain and Anxiety \(PAIN-B\)](#)

[Comprehensive Pain Assessment \(PAIN-C\)](#)

[Cancer Pain Syndromes \(PAIN-D\)](#)

[Opioid Principles, Prescribing, Titration, and Maintenance \(PAIN-E\)](#)

[Management of Opioid Side Effects \(PAIN-F\)](#)

[Co-Analgesics for Neuropathic Pain \(PAIN-G\)](#)

[Psychosocial Support \(PAIN-H\)](#)

[Patient and Family Education \(PAIN-I\)](#)

[Nonpharmacologic Interventions \(PAIN-J\)](#)

[NSAID and Acetaminophen Prescribing \(PAIN-K\)](#)

[Specialty Pain Consultations \(PAIN-L\)](#)

[Interventional Strategies \(PAIN-M\)](#)

[For help using these documents, please click here](#)

[Guidelines Index](#)

[Print the Cancer Pain Guideline](#)

[Discussion](#)

[References](#)

This manuscript is being updated to correspond with the newly updated algorithm.

Clinical Trials: The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN member institutions, [click here: nccn.org/clinical_trials/physician.html](#)

NCCN Categories of Evidence and Consensus: All recommendations are Category 2A unless otherwise specified.

See [NCCN Categories of Evidence and Consensus](#)

These guidelines are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. These guidelines are copyrighted by National Comprehensive Cancer Network. All rights reserved. These guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2009

SUMMARY OF GUIDELINES UPDATES

Summary of changes in the 2009 version of the Adult Cancer Pain guidelines from the 1.2008 version include:

[PAIN-2](#)

- For all pain categories, “Recognize and treat *opioid* side effects” was changed to “Recognize and treat *analgesic* side effects”.

[PAIN-3](#)

- “As clinically indicated for pain crisis” was replaced by, “As indicated for uncontrolled pain (patient goals not met)”.

[PAIN-4](#)

- A new bullet, “Consider opioid rotation if inadequate pain control or persistent side effects from current therapy ([See PAIN-E](#))” was added as a subsequent treatment for pain.

[PAIN-A 1 of 2](#)

- A statement regarding the use of the pain intensity ratings scale was added.
- For the numerical rating scale, the question was modified from “How much pain are you having?” to “What number describes your worst pain in the past 24 hours from 0 (no pain) to 10 (worst pain you can imagine)?” and for the categorical scale, the question was modified to “What is the worst pain you have had in the past 24 hours?”
- A new reference was added to “The Faces Pain Rating Scale”.

[PAIN-C 1 of 2](#)

- Pain experience, “last 24 hours and current pain” were added as time intervals for which pain intensity should be determined.

[PAIN-D](#)

- For bone or neuropathic pain, a new bullet, “For resistant pain, consider referral to a pain specialist and/or the use of interventional strategies” was added.
- For neuropathic pain, “capsaicin” was removed as an example of a topical agent. (Also for [PAIN-G 2 of 2](#))

[PAIN-E 1 of 3](#)

- General principles, bullet 4 was modified as “Switch from *preparations of opioid combined with other medications (such as aspirin or acetaminophen) to pure opioid preparation if opioid dose required would result in excessive or inadequate dosing of the non-opioid component of combination*” and a new bullet “Consider opioid rotation if pain inadequately controlled or persistent side effects from current therapy” was added.

[PAIN-E 2 of 3](#)

- The dosing for methadone was removed from the table and the corresponding footnote 5 was modified by adding, “The oral conversion ratio of methadone varies.”
- Footnote 2 was modified by adding, “These preparations should only be used in opioid tolerant patients.”

[PAIN-E 3 of 3](#)

- “Thin body habitus” was added as an example which may accelerate transdermal fentanyl absorption.
- A new principle for converting or rotating from another opioid to transdermal fentanyl, “When converting from parenteral fentanyl to transdermal fentanyl, a straight 1:1 ratio is appropriate, ie, the number of mcg of parenteral fentanyl per hour should be approximately equal to the number of mcg of transdermal fentanyl per hour” was added.
- Table for recommended dose conversion from other opioids to transdermal fentanyl was added to the page.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued on next page](#)

SUMMARY OF GUIDELINES UPDATES (continued)

PAIN-F 1 of 3

- For preventive measures, “increase fluids” and “increase dietary fiber” were changed to “maintain adequate fluid intake” and “maintain adequate dietary fiber intake” respectively. In addition, the statement “compounds such as Metamucil are unlikely to control opioid induced constipation and are not recommended” was added.
- For patients with persistent constipation and advanced illness receiving palliative care, “consider methylnaltrexone” was added.

PAIN-F 2 of 3

- Preventive measures for nausea, a statement regarding prophylactic treatment was added.
- If nausea develops, “dexamethasone can be considered” was added.

PAIN-F-3 of 3

- “Olanzapine and risperidone” were added as examples of medications to use for delirium.

PAIN-G 2 of 2

- Trial of antidepressants
 - A statement regarding tertiary and secondary amines was added. In addition, the statement regarding anticholinergic adverse effects was clarified by adding, “are more likely to occur with amitriptyline and imipramine.”
 - A starting dose for “duloxetine” was added.
- Trial of anticonvulsants
 - “Lamotrigine” was removed as an example.
 - A new bullet, “Consider other anticonvulsant agents, many of which have been shown to have efficacy in non cancer neuropathic pain” was added.
- Trial of topical agents
 - A new example, “Consider NSAID- diclofenac gel 1%, four times daily; or diclofenac patch 180 mg, one patch daily or one patch twice daily” was added.

PAIN-I

- A new bullet, “Potent analgesics should only be taken as prescribed and by the person for whom the medication is prescribed; do not self adjust dosage or frequency unless discussed with healthcare provider” was added to messages to be conveyed to patient and family.
- A new bullet, “The healthcare team should be familiar with local regulations pertaining to the operation of machinery or motor vehicles while taking potentially sedating medication and advise patient and family accordingly” was added.

PAIN-K

- First bullet, NSAIDs should be used with caution, was modified by adding “thrombocytopenia, or bleeding disorder”.
- Further NSAID decisions, a new bullet, “When systemic administration is not feasible, consider topical NSAID preparations” was added.

PAIN-L

- For substance abuse and diversion consultation, a new bullet “Evaluation for substance use disorder” was added.

PAIN-M

- “Radiofrequency ablation for bone lesions” was added as an example of an interventional approach.
- Footnote 1, medications that increase risk for bleeding was clarified by adding, “anti-angiogenesis agents such as bevacizumab”.


Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

UNIVERSAL SCREENING

ASSESSMENT


MANAGEMENT OF PAIN



Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

To quantify pain intensity,
[See Pain Intensity Rating \(PAIN-A\)](#)

MANAGEMENT OF PAIN IN PATIENTS NOT TAKING OPIOIDS




Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

To quantify pain intensity,
[See Pain Intensity Rating \(PAIN-A\)](#)

RESPONSE TO SEVERE, MODERATE, OR INCREASED PAIN WITH SHORT-ACTING OPIOIDS

Monitor for acute and chronic adverse effects. ([See Management of Opioid Side Effects PAIN-F](#))



^aSubcutaneous can be substituted for intravenous, however subcutaneous route delays onset of effect by up to 30 minutes.


^bInadequate response includes insufficient pain relief as well as the presence of adverse effects due to analgesics.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

To quantify pain intensity,
[See Pain Intensity Rating \(PAIN-A\)](#)

SUBSEQUENT TREATMENT FOR PAIN



Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

ONGOING CARE

Clinician responsibilities

- **Routine follow-up**
 - Assess pain during each outpatient contact or at least each day for inpatients or more frequently based on:
 - ◊ Patient's condition
 - ◊ Institutional standards
 - ◊ Regulatory requirements
- Provide written follow-up pain plan, including prescribed medications ([See PAIN-I](#))
- Ensure adequate access to prescribed medications
- Instruct the patient on the importance of the following:
 - Adherence to medication plan
 - Maintain clinic appointments
 - Contact clinician if pain worsens or side effects inadequately controlled
 - Follow documented plan ([See PAIN-I](#))
- Process realistic goals, revise, and review
- Address system barriers
 - Social services
- Maintain communication and coordinate care with pain specialist and relevant providers
- On-call/as needed availability

Goals of treatment achieved:
• Comfort
• Function

Continue routine follow-up

Goals of treatment NOT achieved:
• Comfort
• Function

[See Universal Assessment and Screening \(PAIN-1\)](#)
[Consider Interventional Strategies \(PAIN-M\)](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

PAIN INTENSITY RATING (1 of 2)

Pain intensity rating scales can be used as part of universal screening and comprehensive pain assessment. At minimum, patients should be asked about "worst" and "usual" pain in the past 24 hours, also "least" and "now" could be asked. For comprehensive assessment, also include "worst pain in past week," "pain at rest," and "pain with movement". [See Comprehensive Pain Assessment \(PAIN-C\)](#) for more details.

Table 1: Numerical Rating Scale

Numerical rating scale:


- Verbal: "What number describes your worst pain in the past 24 hours from 0 (no pain) to 10 (worst pain you can imagine)?"
- Written: "Circle the number that describes your worst pain in the past 24 hours."

0 1 2 3 4 5 6 7 8 9 10
No pain Worst pain you can imagine

Categorical scale:

"What is the worst pain you have had in the past 24 hours?"

None (0), Mild (1–3), Moderate (4–6), or Severe (7–10)

Table 2: The Faces Pain Rating Scale¹

[See Pain Assessment in the Nonverbal Patient on PAIN-A 2 of 2](#)

Instructions: "These faces show how much something can hurt. This face (point to the left-most face) shows no pain. Each face shows more and more pain (point to each face from left to right) up to this one (point to the right-most face)- it shows very much pain. Point to the face that shows how much you hurt (right now)."

¹Ware LJ, Epps CD, Herr K, Packard A. Evaluation of the Revised Faces Pain Scale, Verbal Descriptor Scale, Numeric Rating Scale, and Iowa Pain Thermometer in older minority adults. *Pain Manag Nurs* 2006;7:117-125.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

PAIN INTENSITY RATING (2 of 2)**PAIN ASSESSMENT IN THE NONVERBAL PATIENT¹**

- The inability of patients to verbally communicate pain intensity because of cognitive or physiologic issues is a major barrier relating to pain assessment and management. Therefore, the American Society for Pain Management Nursing (www.aspmn.org) has developed a position statement and clinical practice recommendations clinicians may find useful in caring for such patients.
- In the absence of self-report, observation of behavior is a valid approach to pain assessment with the understanding that behaviors may also indicate another source of distress such as emotional distress. Potential causes and the context of the behavior must be considered when making pain treatment decisions.
- A multi-faceted approach is recommended that combines direct observation, family/caregiver input, and evaluation of response to pain medicines or nonpharmacologic interventions.
- For patients with advanced dementia, a comprehensive review of currently published tools is available at http://prc.coh.org/pain_assessment.asp. These tools are in varying stages of development and validation and include but are not limited to:
 - ▶ The Assessment of Discomfort in Dementia Protocol (ADD)²
 - ▶ Checklist of Nonverbal Pain Indicators (CNPI)³
 - ▶ The Pain Assessment in Advanced Dementia Scale (PAINAD)⁴
- For patients who are intubated and/or are unconscious, pain assessment tools have been tested in specific situations and include but are not limited to:
 - ▶ Behavioral Pain Scale (BPS);⁵ tested in adults and intensive care
 - ▶ Critical-Care Pain Observation Tool (CPOT);⁶ tested in adults and intensive care
- Clinicians are encouraged to monitor current research regarding new developments in strategies and tools for assessing pain in patients who have difficulty with self-report.

¹Herr K, Coyne P, Key T, et al. Pain assessment in the nonverbal patient: Position statement with clinical practice recommendations. Pain Manag Nurs 2006;7:44-52.

²Kovach, CR, Noonan, PE, Griffie J, et al. The assessment of discomfort in dementia protocol. Pain Management Nursing 2002;3:16-27.

³Feldt KS. Checklist of nonverbal pain indicators. Pain Management Nursing 2000;1:13-21.

⁴Lane P, Kuntupis M, MacDonald S, et al. A pain assessment tool for people with advanced Alzheimer's and other progressive dementias. Home Healthc Nurse 2003;21:32-37.

⁵Payen JF, Bru O, Bosson JL, et al. Assessing pain in critically ill sedated patients by using a behavioral pain scale. Crit Care Med 2001;29:2258-2263.

⁶Gélinas C, Johnston C, et al. Pain assessment in the critically ill ventilated adult: validation of the Critical-Care Pain Observation Tool and physiologic indicators. Clin J Pain 2007;23:497-505.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

PROCEDURE-RELATED PAIN and ANXIETY

Events that are expected to cause discomfort to the patient such as diagnostic and therapeutic procedures (eg, IV, arterial line, central line, injection, manipulation, bone marrow aspiration, lumbar puncture, skin biopsy, bone marrow biopsy) as well as transportation/change in position for a patient with a fracture, should merit pre-treatment with an analgesic intervention. Additional analgesics and/or local anesthetics should be available immediately for further titration by the caregiver as needed.

Consistent adequate analgesia for all pain-related procedures and anxiety is critical. Intervention may be multi-modal and include one or more of the following techniques as appropriate.

- Local anesthetics such as:
 - ▶ Topical local anesthetics creams (containing lidocaine, prilocaine, tetracaine) applied to intact skin with sufficient time for effectiveness as per package insert.
 - ▶ Physical approaches (ultrasound, cutaneous warming, laser or jet injection) may accelerate the onset of cutaneous anesthesia.
 - ▶ Ionophoretic devices to provide lidocaine delivery through the skin without needles in 10-15 minutes.
 - ▶ Subcutaneous administration of lidocaine with a 27 gauge needle.
- Administration of sedatives/analgesics/general anesthesia by trained personnel.
- Additional nonpharmacologic interventions ([See PAIN-J](#))

Providing information regarding all of these analgesic techniques prior to the procedure is ideal as it allows the patient and their family the time they may need to assimilate all of the information, ask questions, and master the techniques while reducing anticipatory anxiety.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

COMPREHENSIVE PAIN ASSESSMENT

Patient's self report of pain is the standard of care. If the patient is unable to speak normally, an alternative method to obtain pain rating and response should be utilized ([See PAIN-A 2 of 2](#)).

- Pain Experience

- ▶ Location, referral pattern, radiation of pain(s)
- ▶ Intensity [See Pain Intensity Rating \(PAIN-A\)](#)
 - ◊ Last 24 hours and current pain
 - ◊ At rest and with movement
- ▶ Interference with activities [See Impact of Pain Measurement \(PAIN-C 2 of 2\)](#)
 - ◊ General activity, mood, relationship with others, sleep, appetite
- ▶ Timing: onset, duration, course, persistent, or intermittent
- ▶ Description or quality
 - ◊ Aching, stabbing, throbbing, pressure often associated with somatic pain in skin, muscle, bone
 - ◊ Gnawing, cramping, aching, sharp often associated with visceral pain in organs or viscera
 - ◊ Sharp, tingling, ringing, shooting often associated with neuropathic pain caused by nerve damage
- ▶ Aggravating and alleviating factors
- ▶ Other current symptoms
- ▶ Current pain management plan, both pharmacologic and non-pharmacologic. If medications are used, determine
 - ◊ What medication(s), prescription and/or over the counter?
 - ◊ How much?
 - ◊ How often?
 - ◊ Current prescriber?
- ▶ Response to current therapy
 - ◊ Pain relief
 - ◊ Patient adherence to medication plan
 - ◊ Medication side effects such as constipation, sedation, cognitive slowing, nausea, others
- ▶ Prior pain therapies
 - ◊ Reason for use, length of use, response, reasons for discontinuing

- ▶ Special issues relating to pain
 - ◊ Meaning of pain for patient and family
 - ◊ Patient and family knowledge and beliefs surrounding pain and pain medications
 - ◊ Cultural beliefs toward pain
 - ◊ Spiritual or religious considerations
 - ◊ Patient goals and expectations regarding pain management
- Psychosocial
 - ▶ Patient distress [See NCCN Distress Management Guidelines](#)
 - ▶ Family and other support
 - ▶ Psychiatric history including current or prior history of substance abuse
 - ▶ Risk factors for aberrant use or diversion of pain medication
 - ◊ Patient factors, environmental, and social factors
 - ▶ Risk factors for undertreatment of pain
 - ◊ Pediatric, geriatric, minorities, female, communication barriers, history of substance abuse, neuropathic pain, and cultural factors
- Medical history
 - ▶ Oncologic treatment including current and prior chemotherapy, radiation therapy, and surgery
 - ▶ Other significant illnesses
 - ▶ Pre-existing chronic pain
- Physical examination
- Relevant laboratory and imaging studies to evaluate for disease progression
- The endpoint of the assessment is to establish the “pain diagnosis” and individualized pain treatment plan based on mutually developed goals. The “pain diagnosis” includes the etiology and pathophysiology of pain:
 - ▶ Etiology
 - ◊ Cancer
 - ◊ Cancer therapy (RT, chemotherapy, surgery) or procedures
 - ◊ Coincidental or noncancer
 - ▶ Pathophysiology
 - ◊ Nociceptive
 - ◊ Neuropathic

[Return to Initial Screening \(PAIN-1\)](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

IMPACT OF PAIN MEASUREMENT^{1,2,3}

Mark the number that describes how much, in the past [week / 24 hours] pain has interfered with your:

<p>1. General Activity</p> <p>0 1 2 3 4 5 6 7 8 9 10</p> <p>Does not Interfere Completely Interferes</p>
<p>2. Mood</p> <p>0 1 2 3 4 5 6 7 8 9 10</p> <p>Does not Interfere Completely Interferes</p>
<p>3. Walking Ability</p> <p>0 1 2 3 4 5 6 7 8 9 10</p> <p>Does not Interfere Completely Interferes</p>
<p>4. Normal Work (includes both work outside the home and housework)</p> <p>0 1 2 3 4 5 6 7 8 9 10</p> <p>Does not Interfere Completely Interferes</p>
<p>5. Relations with other people</p> <p>0 1 2 3 4 5 6 7 8 9 10</p> <p>Does not Interfere Completely Interferes</p>
<p>6. Sleep</p> <p>0 1 2 3 4 5 6 7 8 9 10</p> <p>Does not Interfere Completely Interferes</p>
<p>7. Enjoyment of life</p> <p>0 1 2 3 4 5 6 7 8 9 10</p> <p>Does not Interfere Completely Interferes</p>

¹Cleeland CS, Nakamura Y, Mendoza et al. Dimensions of the impact of cancer pain in a four country sample: New information from multidimensional scaling. Pain 1996;67:267-273.

²Serlin RC, Mendoza TR, Nakamura Y, et al. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995;61:277-284.

³For the complete Brief Pain Inventory assessment tool, see <http://www.mdanderson.org/departments/PRG/>

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

CANCER PAIN SYNDROMES

- Pain associated with inflammation:
 - ▶ Trial of NSAIDs or glucocorticoids

- Nerve compression or inflammation:
 - ▶ Trial of glucocorticoids

- Bone pain without oncologic emergency:
 - ▶ NSAIDs and titrate analgesic to effect [See Nonsteroidal Anti-inflammatory Drugs \(NSAID\) and Acetaminophen Prescribing \(PAIN-K\)](#)
 - ▶ Local bone pain: consider local radiation therapy or nerve block (eg, rib pain)
 - ▶ Diffuse bone pain: consider trial of bisphosphonates, hormonal or chemotherapy, glucocorticoids and/or systemic administration of radioisotopes
 - ▶ Consider physical medicine evaluation [See Pain Specialty Consultation \(PAIN-L\)](#)
 - ▶ For resistant pain, consider referral to a pain specialist and/or the use of interventional strategies. [See Interventional Strategies \(PAIN-M\)](#)

- Neuropathic pain:
 - ▶ Trial of anticonvulsant: start with low dose and increase every 3-5 days if tolerated or lengthen interval up to 14 days (eg, gabapentin, 100-1,200 mg three times a day; carbamazepine, 100-400 mg two times a day; pregabalin 100-600 mg/d divided in 2-3 doses, or other anticonvulsants and/or
 - ▶ Trial of antidepressant: start with low dose and increase every 3-5 days if tolerated or lengthen interval up to 14 days (eg, nortriptyline, 10-150 mg/d; doxepin, 10-150 mg/d; desipramine, 10-150 mg/d; venlafaxine, 37.5-225 mg/d divided in 2-3 doses; duloxetine, 30-60 mg/d and/or
 - ▶ Consider topical agents such as local anesthetics including lidocaine patch
 - ▶ For resistant pain, consider referral to a pain specialist and/or the use of interventional strategies. [See Interventional Strategies \(PAIN-M\)](#)

- Painful lesions that are likely to respond to antineoplastic therapies:
 - ▶ Consider trial of radiation, hormones, or chemotherapy

- For severe refractory pain in the imminently dying, [See NCCN Palliative Care Guideline.](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

OPIOID PRINCIPLES, PRESCRIBING, TITRATION, AND MAINTENANCE (1 of 3)**I. GENERAL PRINCIPLES**

- The appropriate dose is the dose that relieves the patient's pain throughout the dosing interval without causing unmanageable side effects.
- Calculate dosage increase based upon total opioid dose (around the clock/scheduled and as needed) taken in the previous 24 h.
- Increase both around the clock and as needed doses. The rapidity of dose escalation should be related to the severity of the symptoms. [See Response to Severe, Moderate or Increased Pain with Short-Acting Opioids \(PAIN-3\)](#).
- Switch from preparations of opioid combined with other medications (such as aspirin or acetaminophen) to pure opioid preparation if opioid dose required would result in excessive or inadequate dosing of the non-opioid component of combination. (See [PAIN-K](#))
- If patient is experiencing unmanageable side effects and pain is < 4, consider downward dose titration by approximately 25% and reevaluate. Patient would require close follow-up to make sure pain did not escalate.
- Equilibrium is achieved in about 5 half lives.
- Consider opioid rotation if pain inadequately controlled or persistent side effects from current therapy.
- To convert or rotate from one opioid to another:
 1. Total the amount of current opioid(s) taken in a 24-hour period that effectively controls pain.
 2. Calculate the equianalgesic dose of the new opioid. [See Oral And Parenteral Opioid Equivalences and Relative Potency of Drugs as Compared with Morphine Based on Single Dose Studies \(PAIN-E 2 of 3\)](#).
 3. If pain was effectively controlled, reduce the dose by 25-50% to allow for incomplete cross-tolerance between different opioids. During the first 24 hours, titrate liberally and rapidly to analgesic effect. If previous dose was ineffective, may begin with 100% of equianalgesic dose or increase that by 25%.
 4. Lastly, divide the total daily dose of new opioid needed by the number of doses per day to determine the individual dose (eg, 6 doses for regular PO morphine every 4 hrs; 2 doses for extended release morphine every 12 hours).

II. PRINCIPLES OF MAINTENANCE OPIOID THERAPY

- For continuous pain, it is appropriate to give pain medication on a regular schedule with supplemental doses for breakthrough pain.
- Consider converting from short-acting opioids to extended release opioids for control of chronic persistent pain when 24 h opioid requirement is stable.
- Provide rescue doses of short-acting opioids for pain not relieved by extended release opioids including breakthrough pain or acute exacerbations of pain, activity or position related pain, or pain at the end of dosing interval:
 - For rescue doses, use short-acting formulation used for regular-scheduled dosing.
 - Allow rescue doses of short-acting opioids of 10% to 20% of 24-h oral dose (mg) every 1 h as needed
 - Consider transmucosal lozenge or buccal tablet fentanyl for brief episodes of acute exacerbation of pain not attributed to inadequate dosing of around the clock opioid. Data do not support a specific transmucosal fentanyl dose equianalgesic to other opioids. Initiate transmucosal fentanyl with lowest dose (200 mcg lozenge or 100 mcg buccal tablet) and titrate to effect.
- Increase dose of extended release opioid if patient persistently needs doses of as needed opioids or when dose of around the clock opioid fails to relieve pain at peak effect or at end of dose.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued on next page](#)

OPIOID PRINCIPLES, PRESCRIBING, TITRATION, AND MAINTENANCE (2 of 3)

III. ORAL AND PARENTERAL OPIOID EQUIVALENCES AND RELATIVE POTENCY OF DRUGS AS COMPARED WITH MORPHINE BASED ON SINGLE DOSE STUDIES

<u>Opioid Agonists</u>	<u>Parenteral Dose</u>	<u>Oral Dose</u>	<u>Factor (IV to PO)</u>	<u>Duration of Action¹</u>
Codeine	130 mg	200 mg	1.5	3-4 h
Fentanyl ²	100 mcg	--	--	1-3 h
Hydrocodone ³	--	30-200 mg	--	3-5 h
Hydromorphone	1.5 mg	7.5 mg	5	2-3 h
Levorphanol ⁴	2 mg	4 mg	2	3-6 h
Methadone ^{4,5}	--	--	--	--
Morphine ⁶	10 mg	30 mg	3	3-4 h
Oxycodone	--	15-20 mg	--	3-5 h
Oxymorphone	1 mg	10 mg	10	3-6 h
Tramadol ⁷	--	50-100 mg	--	3-7 h

NOT RECOMMENDEDMeperidine⁸Propoxyphene⁸Partial agonists (buprenorphine)⁹Mixed agonist-antagonists
(pentazocine, nalbuphine,
butorphanol, dezocine)⁹

Special Note: Partial agonists and mixed agonists-antagonists have limited usefulness in cancer pain. They should NOT be used in combination with opioid agonist drugs. Converting from an agonist to an agonist-antagonist could precipitate a withdrawal crisis in the opioid dependent patient.

¹ Shorter time generally refers to parenterally administered opioids (except for controlled-release products which have some variability); longer time generally applies to oral dosing.

² Available in transdermal system for extended dosing (see instructions on [PAIN-E 3 of 3](#)) and oral transmucosal or buccal systems for breakthrough pain. These preparations should only be used in opioid tolerant patients.

³ Equivalence data not substantiated. Clinical experience suggests use as a mild, initial use opioid but effective dose may vary. Usually combined with ASA or acetaminophen in doses from 325 to 750 mg. Dosage must be monitored for safe limits of ASA or acetaminophen. Dose listed refers only to opioid portion.

⁴ Long half-life, observe for drug accumulation and side effects after 2-5 days. May need to be dosed every 4 h initially then changed to every 6-8 h after steady state achieved (1-2 wks).

⁵ The oral conversion ratio of methadone varies. PRACTITIONERS ARE ADVISED TO CONSULT WITH A PAIN OR PALLIATIVE CARE SPECIALIST IF THEY ARE UNFAMILIAR WITH METHADONE PRESCRIBING.

⁶ Conversion factor listed for chronic dosing. Avoid using morphine in renal failure due to accumulation of morphine-6-glucuronide metabolite.

⁷ Weak opioid receptor agonist with some antidepressant activity. For mild to moderate pain. Recommended dose of 100 mg four times a day (maximum daily dose 400 mg) to avoid CNS toxicity. Even at maximum dose 100 mg four times a day, tramadol is less potent than other opioid analgesics such as morphine.

⁸ Not recommended for long term or high dose use because of CNS toxic metabolites (normeperidine, norpropoxyphene).

⁹ Partial agonists and mixed agonist-antagonists may produce withdrawal in opioid-dependent patients.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued on next page](#)

OPIOID PRINCIPLES, PRESCRIBING, TITRATION, AND MAINTENANCE (3 of 3)

IV. CONVERT OR ROTATE FROM ANOTHER OPIOID TO TRANSDERMAL FENTANYL

1. Pain should be relatively well-controlled on a short acting opioid prior to initiating the patch. Patches are NOT recommended for unstable pain requiring frequent dose changes.
2. Determine 24 hour parenteral morphine equivalent requirement using the table [Oral And Parenteral Opioid Equivalences and Relative Potency of Drugs as Compared with Morphine Based on Single Dose Studies \(PAIN-E 2 of 3\)](#).
3. Select the mcg per hour dose according to the ranges listed below. For dosage requirements > 100 mcg/hr, multiple patches can be used.
4. The patch duration is usually 72 hours. Duration in some may be only 48 hours; thin body habitus, fever, or topical application of heat (such as heat from heat lamps, electric blankets, etc.) may accelerate transdermal fentanyl absorption and are contraindications for transdermal fentanyl.
5. An as needed (prn) dose of morphine or other short-acting opioid should be prescribed and may be needed particularly during the first 8-24 hours. Increase the patch dosage based on the average amount of additional opioid required over the 72 hour period. Continue breakthrough medication once the patch dose is stabilized.
6. When converting from parenteral fentanyl to transdermal fentanyl, a straight 1:1 ratio is appropriate, ie, the number of mcg of parenteral fentanyl per hour should be approximately equal to the number of mcg of transdermal fentanyl per hour.

Recommended Dose Conversion From Other Opioids to Transdermal Fentanyl¹

Transdermal Fentanyl	Morphine ²		Oxycodone		Hydromorphone		Codeine	
	IV/SubQ *	Oral	IV/SubQ *	Oral	IV/SubQ *	Oral	IV/SubQ *	Oral
25 mcg/h	20 mg/d	60 mg/d	15 mg/d	30 mg/d	1.5 mg/d	7.5 mg/d	130 mg/d	200 mg/d
50 mcg/h	40 mg/d	120 mg/d	30 mg/d	60 mg/d	3.0 mg/d	15.0 mg/d	260 mg/d	400 mg/d
75 mcg/h	60 mg/d	180 mg/d	45 mg/d	90 mg/d	4.5 mg/d	22.5 mg/d	390 mg/d	600 mg/d
100 mcg/h	80 mg/d	240 mg/d	60 mg/d	120 mg/d	6.0 mg/d	30.0 mg/d	520 mg/d	800 mg/d

* Parenteral dosing such as IV (intravenous) or SubQ (subcutaneous)

NOTE: Due to patient variability the doses suggested in this guide are approximate and clinical judgement must be used to titrate to the desired response.

¹Breitbart W, Chandler S, Egel B, et al. An alternative algorithm for dosing transdermal fentanyl for cancer-related pain. *Oncology* 2000;14:695-702.

²Equianalgesic doses to morphine adapted from Foley K. The treatment of cancer pain. *N Engl J Med* 1985;313:84-95.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

MANAGEMENT OF OPIOID SIDE EFFECTS (1 of 3)Principles of Management of Opioid Side Effects

- Tolerance generally develops, except with constipation. Maximize non-opioid and nonpharmacologic interventions to limit opioid dose and treat side effects. If side effects persist, consider opioid rotation.
- Multisystem assessment is necessary.
- Recognize that pain is rarely treated in isolation in cancer. Symptoms need to be evaluated as contributing factors.

Constipation

- Preventive measures
 - Prophylactic medications
 - ◊ Stimulant laxative + stool softener (eg, senna with docusate, 2 tablets every morning; maximum 8-12 tablets per day).
 - ◊ Increase dose of laxative when increasing dose of opioids
 - Maintain adequate fluid intake
 - Maintain adequate dietary fiber intake. Compounds such as Metamucil are unlikely to control opioid induced constipation and are not recommended.
 - Exercise, if feasible
- If constipation develops
 - Assess for cause and severity of constipation
 - Rule out obstruction
 - Treat other causes
 - Titrate stool softener/laxatives as needed with goal of one non-forced bowel movement every 1-2 d
 - Consider co-analgesic to allow reduction of the opioid dose
- If constipation persists
 - Reassess for the cause and severity of constipation, rule out bowel obstruction
 - Check for impaction
 - Consider adding another agent, such as magnesium hydroxide, 30-60 mL daily; bisacodyl, 2-3 tablets PO daily, or 1 rectal suppository daily; lactulose, 30-60 mL daily; sorbitol, 30 mL every 2 h x 3, then as needed, or magnesium citrate, 8 oz PO daily, polyethylene glycol (1 capful/8 oz water PO two times a day)
 - Fleet, saline, or tap water enema
 - Consider use of a prokinetic agent (eg, metoclopramide, 10-20 mg PO four times a day)
 - For patients with advanced illness receiving palliative care, consider methylnaltrexone, 0.15 mg/kg subcutaneously, maximum one dose per day
 - Consider neuraxial analgesics or neuroablative techniques to potentially reduce opioid dose

**MANAGEMENT OF OPIOID
SIDE EFFECTS continued
on next page**

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

MANAGEMENT OF OPIOID SIDE EFFECTS (2 of 3)Nausea

• Preventive measures

- For patients with a prior history of opioid induced nausea, prophylactic treatment with antiemetic agents (see below) are highly recommended.

• If nausea develops

- Assess for other causes of nausea (eg, constipation, central nervous system pathology, chemotherapy, radiation therapy, hypercalcemia)
- Consider prochlorperazine, 10 mg PO every 6 h as needed; or thiethylperazine, 10 mg PO every 6 h as needed; or haloperidol, 0.5-1 mg PO every 6-8 h; or metoclopramide, 10-20 mg PO every 6 h as needed
- If nausea persists despite as needed regimen, administer antiemetics around the clock for 1 wk, then change to as needed
- Consider adding a serotonin antagonist (eg, granisetron, 2 mg PO daily; or ondansetron, 8 mg PO three times a day; or dolasetron 100-200 mg PO; or palonosetron 300 mcg/kg IV). Use with caution as constipation is a side effect.
- Dexamethasone can be considered

• If nausea persists for more than 1 wk

- Reassess cause and severity of nausea
- Consider opioid rotation

• If nausea persists after a trial of several opioids and above measures

- Reassess cause and severity of nausea
- Consider neuraxial analgesics or neuroablative techniques to potentially reduce opioid dose

Pruritus

• If pruritus develops

- Assess for other causes (other medications, etc.)
- Consider antihistamines such as diphenhydramine, 25-50 mg IV or PO every 6 h; or promethazine, 12.5-25 mg PO every 6 h

• If pruritus persists

- Consider changing to another opioid if symptomatic management has failed.
- Consider adding to analgesic regimen: small doses of mixed agonist-antagonist, nalbuphine, 0.5-1 mg IV every 6 h as needed

• Consider continuous infusion of naloxone, 0.25 mcg/kg/h and titrate up to 1 mcg/kg/h for relief of pruritus without decreasing effectiveness of the analgesic.

[MANAGEMENT OF OPIOID SIDE EFFECTS continued on next page](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

MANAGEMENT OF OPIOID SIDE EFFECTS (3 of 3)Delirium

- Assess for other causes of delirium (eg, hypercalcemia, CNS, metastases, other psychoactive medications, etc.)
- If one cannot determine other possible causes of delirium, consider changing the opioid
- Consider nonopioid analgesic to allow reduction of the opioid dose
- Consider haloperidol, 0.5-2 mg PO or IV every 4-6 h; or olanzapine, 2.5-5 mg PO or sublingual every 6-8 h; or risperidone, 0.25-0.5 mg 1-2 times day
- For further information about delirium, [See NCCN Palliative Care Guidelines](#)

Motor and Cognitive Impairment

- Studies have shown that stable doses of opioids (> 2 wk) are not likely to interfere with psychomotor and cognitive function but these functions should be monitored during analgesic administration and titration.

Respiratory depression

- Use reversing agents cautiously. If reversing an opioid with a long half life such as methadone, consider naloxone infusion.
- If respiratory problems or acute changes in mental status occur, consider naloxone administration. Dilute one ampule of naloxone (0.4 mg/1 mL) into 9 mL of normal saline for a total volume of 10 mL. Give 1-2 mL (0.04-0.08 mg) every 30-60 seconds until improvement in symptoms is noted. Be prepared to repeat this process (the half-life of opioids is generally longer than that of the naloxone). If the patient is not responsive within 10 minutes and total naloxone dose of 1 mg, consider another reason for the change in neurological status.

Sedation

- If sedation develops and persists for more than 1 wk after initiating opioids
 - Assess for other causes of sedation (eg, CNS pathology, other sedating medications, hypercalcemia, dehydration, sepsis, hypoxia)
 - Decrease the dose of opioid if pain control can be maintained at a lower dose
 - Consider changing the opioid
 - Consider nonopioid analgesic to allow reduction of the opioid dose
 - Consider a lower dose of opioid given more frequently, to decrease peak concentrations
 - Consider the addition of caffeine, 100-200 mg PO every 6 h; or methylphenidate, 5-10 mg 1-3 times per day; or dextroamphetamine, 5-10 mg PO 1-3 times per day; or modafinil, 100-200 mg per day. When using CNS stimulants for sedation, limit dosing to morning and early afternoon to avoid insomnia at night.
- If sedation persists despite several changes of opioids and the above measures
 - Reassess cause and severity of sedation
 - Consider neuraxial analgesics or neuroablative techniques to potentially reduce opioid dose

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

CO-ANALGESICS FOR NEUROPATHIC PAIN
(ANTIDEPRESSANTS, ANTICONVULSANTS, AND TOPICAL AGENTS)

PRINCIPLES OF CO-ANALGESIC USE

- Antidepressant and anticonvulsants are first-line co-analgesics for the treatment of cancer-related neuropathic pain.
- These drugs can be helpful for patients whose pain is only partially responsive to opioids.
- The use of co-analgesics in the cancer population is still often guided solely by anecdotal experience or guidelines derived from data in non-malignant pain populations.
- Effective use is predicated on an assessment that clarifies the nature of the pain.
- As with opioids, it is likely that response to different co-analgesics may vary among types of neuropathic pain and individual patients.
- Drug selection may be influenced by the presence of certain non-pain symptoms and co-morbidities. For example, a sedating drug may be useful in a patient in whom insomnia is a problem.
- Patient education should emphasize the trial and error nature of the treatment so patients do not get discouraged.
- Doses should be increased until the analgesic effect is achieved, side effects become unmanageable, or the conventional maximal dose is reached.

[See Examples of Co-Analgesics Use for Neuropathic Pain \(PAIN-G 2 of 2\)](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

**CO-ANALGESICS FOR NEUROPATHIC PAIN
(ANTIDEPRESSANTS, ANTICONVULSANTS, AND TOPICAL AGENTS)**

EXAMPLES OF CO-ANALGESIC USE

- **Trial of antidepressant:** Analgesic effectiveness is not dependent on its antidepressant activity. Effective analgesic dose is often lower than that required to treat depression. The onset of analgesic action is usually earlier. Frequently used as a co-analgesic in combination with an opioid for the neuropathic component of the pain.
 - ▶ Tricyclic antidepressants (eg, amitriptyline, imipramine, nortriptyline, desipramine)
 - ◊ Start with low dose and increase every 3- 5 days if tolerated. (eg, nortriptyline and desipramine starting dose 10- 25 mg nightly increase to 50- 150 mg nightly. The tertiary amines (amitriptyline, imipramine) may be more efficacious but secondary amines (nortriptyline, desipramine) are better tolerated. Anticholinergic adverse effects such as sedation, dryness of mouth, urinary hesitancy are more likely to occur with amitriptyline and imipramine.)
 - ▶ Other examples:
 - ◊ Duloxetine- Starting dose 30- 60 mg daily increase to 60- 120 mg daily
 - ◊ Venlafaxine- Starting dose 50- 75 mg daily, increase to 75- 225 mg daily
 - ◊ Bupropion- Starting dose 100- 150 mg daily increase to 150- 450 mg daily
- **Trial of anticonvulsants:** Frequently used as a co-analgesic in combination with an opioid for the neuropathic component of the pain.
 - ▶ Anticonvulsant examples:
 - ◊ Gabapentin- Starting dose 100- 300 mg nightly, increase to 900- 3,600 mg daily in divided doses two times a day to three times a day. Dose increments of 50-100% every 3 days. Slower titration for the elderly, medically frail, or those with renal insufficiency.
 - ◊ Pregabalin- Starting dose 50 mg three times a day, increase to 100 mg three times a day. Lower doses in elderly and those with renal insufficiency. Pregabalin more efficiently absorbed through the GI tract than gabapentin. Titration to the analgesic dose requires just 2 or 3 steps, rather than the multiple steps frequently required with gabapentin.
 - ◊ Consider other anticonvulsant agents, many of which have been shown to have efficacy in non cancer neuropathic pain.
- **Trial of topical agents:** Act locally and may be used as a co-analgesic in combination with an opioid, antidepressant, and/or an anticonvulsant.
 - ▶ Topical Agent Examples:
 - ◊ Lidocaine patch- 5% - Apply daily to the painful site. Minimal systemic absorption.
 - ◊ Consider NSAID- diclofenac gel 1%, four times daily; or diclofenac patch 180 mg, one patch daily or one patch twice daily
- **Trial of corticosteroids:** Long half-life of these drugs allows for once daily dosing. Useful in the acute management of a pain crisis when neural structures or bones are involved. Long-term adverse effects significant.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

PSYCHOSOCIAL SUPPORTSupport

- Inform patient and family that emotional reactions to pain are normal and are evaluated and treated as part of pain treatment.
- Provide emotional support to patients and families that acknowledges the pain is a problem to be addressed.
- Assist in accessing treatment as needed.
- State that you will work together with the patient and family as part of the team to address the pain problem.
- Describe the plan of action to be taken and when results can be expected.
- Express your commitment to staying available until the pain is better managed.
- Verbally repeat your concern and the plan of action to be taken.
- Inform patient and family that there is ALWAYS something else that can be done to try to adequately manage pain and other noxious symptoms.

Skills training

- Teach coping skills to provide pain relief, enhance a sense of personal control, and refocus energy on optimizing quality of life.
- Coping skills for acute pain include Lamaze-type breathing exercises, distraction techniques, and cognitive coping statements to encourage assertiveness and to maximize comfort.
- Coping skills for chronic pain (not pain emergency) include all of the above plus relaxation techniques, guided imagery, graded task assignments, and hypnosis to maximize function.
- Educate patient and family that pain management is a team effort. Members of the team may include: oncologist, nurse, pain specialist, palliative care clinician, physiatry, neurologist, psychologist, social worker, psychiatrist, physical therapist, and spiritual counselor. [See Patient and Family Education \(PAIN-I\)](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

PATIENT AND FAMILY EDUCATION

- **Messages to be conveyed to patient and family**
 - ▶ Relief of pain is important and there is no benefit to suffering with pain.
 - ▶ Pain can usually be well controlled with medications taken by mouth.
 - ▶ If these medications do not work, many other options are available.
 - ▶ Potent analgesics should be taken only as prescribed and by the person for whom the medication is prescribed; do not self adjust dosage or frequency unless discussed with healthcare provider.
 - ▶ Morphine and morphine-like medications are often used to relieve pain.
 - ◊ When these drugs are used to treat cancer pain, addiction is rarely a problem.
 - ◊ If you take these medications now, they will still work later.
 - ◊ These are controlled substances that need to be properly safeguarded in the home.
 - ◊ These medications must be used with caution, and should not be mixed with alcohol or illicit substances.
 - ▶ Communication with the doctors and nurses is critical.
 - ◊ Doctors and nurses cannot tell how much pain you have unless you tell them.
 - ◊ Doctors and nurses want to know about any problems that you think the pain medications may be causing, as there are probably ways to make these better.
 - ◊ Tell your doctor or nurse if you are having any difficulty getting your medication or concerns about taking them. They have dealt with such issues before and will help you.
 - ◊ Expect optimal treatment for pain and side effects. Inform patient of right to expect pain treatment as part of overall care.
- **The following must be reviewed with each patient and family and provided in written form, which is dated:**
 - ▶ A list of each medication prescribed, a description of what each medication is for, and instructions as to how and when to take each one
 - ▶ A list of potential side effects of these medications and what to do if they occur
 - ▶ A list of all medications to be discontinued
 - ▶ A list of telephone numbers to reach an appropriate healthcare professional and specific instructions to call regarding:
 - ◊ Any problems in getting the prescriptions or taking the medication
 - ◊ New pain, change in pain, or pain not relieved with medication
 - ◊ Nausea and vomiting that prevents eating for 1 day
 - ◊ No bowel movements for 3 days
 - ◊ Difficulty arousing the patient from sleep easily during the daytime
 - ◊ Confusion
 - ▶ A plan for follow-up visits and/or phone calls.
- **The healthcare team should be familiar with local regulations pertaining to the operation of machinery or motor vehicles while taking potentially sedating medication and advise patient and family accordingly.**

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

NONPHARMACOLOGIC INTERVENTIONS

Consider nonpharmacologic interventions for:

Pain likely to be relieved or function improved with physical, cognitive or interventional modalities

• Physical modalities

- ▶ Bed, bath, and walking supports
- ▶ Positioning instruction
- ▶ Physical therapy
- ▶ Massage
- ▶ Heat and/or ice
- ▶ TENS
- ▶ Acupuncture or acupressure
- ▶ Ultrasonic stimulation

• Cognitive modalities

- ▶ Imagery/hypnosis
- ▶ Distraction training
- ▶ Relaxation training
- ▶ Active coping training
- ▶ Graded task assignments, setting goals, pacing and prioritizing
- ▶ Cognitive behavioral training
- ▶ Depression/Distress consultation [See NCCN Distress Management Guidelines](#)
- ▶ Consider pain and palliative care specialty consultation [See NCCN Palliative Care Guidelines](#)
 - ◊ Complex management
 - ◊ Diagnosis and treatment of underlying condition
- ▶ Spiritual care

[See Interventional Strategies \(PAIN-M\)](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAID) AND ACETAMINOPHEN PRESCRIBING

- Use NSAIDs with caution in patients at high risk for renal, GI, cardiac toxicities, thrombocytopenia, or bleeding disorder.
- Use any NSAID that the patient has found effective and tolerated well in the past, otherwise consider ibuprofen to the maximal dose.
 - ▶ Ibuprofen, 400 mg four times a day (daily maximum = 3,200 mg)
 - ▶ If needed, consider short term use of ketorolac, 15-30 mg IV every 6 hr for maximum of 5 days
 - ▶ Compounds that do not inhibit platelet aggregation:
 - ◊ Nonacetylated salicylate
 - ◊ Choline + magnesium salicylate combinations, 1.5-4.5 g/d in three divided doses
 - ◊ Salsalate, 2-3 g/d in two or three divided doses
 - ◊ Selective COX-2 inhibitor
 - ▶ Other nonopioid analgesics:
 - ◊ Acetaminophen, 650 mg every 4 h or 1 g every 6 h (daily maximum 4 g/d)
(use caution with combination opioid-acetaminophen products to prevent excess acetaminophen ingestion)
 - ▶ Patients at high risk for:
 - ◊ Renal toxicities: age > 60 y, compromised fluid status, interstitial nephritis, papillary necrosis, and concomitant administration of other nephrotoxic drugs (including cyclosporin, cisplatin) and renally excreted chemotherapy
 - ◊ GI toxicities: age > 60 y, history of peptic ulcer disease or excess alcohol use, major organ dysfunction, high-dose NSAIDs given for long periods
 - ◊ Cardiac toxicities: history of cardiovascular disease or at risk for cardiovascular disease¹
 - ▶ Monitoring for toxicities:
 - ◊ Baseline blood pressure, BUN, creatinine, CBC, and fecal occult blood
 - ◊ Repeat every 3 mo to ensure stability
 - ▶ Treatment of toxicities:
 - ◊ Renal toxicities: discontinue NSAID if BUN or creatinine doubles or if hypertension develops or worsens
 - ◊ GI toxicities: if patient develops gastric upset or nausea, consider discontinuing NSAID or changing to selective COX-2 inhibitor. Consider adding antacids, H₂ receptor antagonists, misoprostol, omeprazole. If patient develops gastrointestinal peptic ulcer or gastrointestinal hemorrhage, discontinue NSAID.
 - ◊ Cardiac toxicities: discontinue NSAID if hypertension develops or worsens
- Further NSAID decisions:
 - ▶ If two NSAIDs are tried in succession without efficacy, use another approach to analgesia
 - ▶ If NSAIDs are effective but treatment is limited by toxicities that are not deemed serious, consider trial of another NSAID
 - ◊ COX-2 inhibitors are associated with lower incidence of GI side effects and do not inhibit platelet aggregation, however, they have not been demonstrated to have reduced renal side effects.
 - ▶ When systemic administration is not feasible, consider topical NSAID preparations.
 - ▶ Toxicity of anti-cancer treatment may increase the risk profile of anti-inflammatory treatment

¹Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians. A scientific statement from the American Heart Association. *Circulation* 2007;115(12):1634-1642.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

PAIN SPECIALITY CONSULTATION

Major indication for referral is:

Pain likely to be relieved or function improved with physical, cognitive, or interventional modalities delivered by a specialty service provider. Note the specific provider of these services may vary in different treatment settings.

- Physical/occupational therapy, rehabilitation/mobility specialists
 - ▶ Physical modalities
 - ◊ Bed, bath, and walking supports
 - ◊ Positioning instruction
 - ◊ Physical therapy
 - ◊ Massage
 - ◊ Heat and/or ice
 - ◊ TENS
 - ◊ Acupuncture or acupressure
 - ◊ Ultrasonic stimulation
- Psychological supportive services, psychologists, counselors
 - ▶ Cognitive modalities
 - ◊ Imagery/hypnosis
 - ◊ Distraction training
 - ◊ Relaxation training
 - ◊ Active coping training
 - ◊ Graded task assignments, setting goals, pacing and prioritizing
 - ◊ Cognitive behavioral training
- Substance abuse and diversion consultation if questions/concerns about medication misuse or diversion
 - ▶ Evaluation for substance use disorder
 - ▶ Assist with establishing treatment agreements, limit setting, single provider/ pharmacy as needed
 - ▶ Communicate regarding need to accomplish pain relief, but avoid misuse/diversion
- Depression/Distress consultation [See NCCN Distress Management Guidelines](#)
- Consider pain and palliative care specialty consultation [See NCCN Palliative Care Guidelines](#)
 - ▶ Consider interventional strategies ([See PAIN-M](#))
 - ▶ Complex management
 - ▶ Diagnosis and treatment of underlying condition
- Spiritual care- determine importance to patient/family and current availability of support

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

INTERVENTIONAL STRATEGIES

Interventional consultation

- Major indications for referral:
 - ▶ Pain likely to be relieved with nerve block (eg, pancreas/ upper abdomen with celiac plexus block, lower abdomen with superior hypogastric plexus block, intercostal nerve, or peripheral nerve)
 - ▶ Failure to achieve adequate analgesia without intolerable side effects (may be handled with intraspinal agents, blocks, spinal cord stimulation, or destructive neurosurgical procedures)

Interventional approaches are appropriate

- Commonly used procedures:
 - ▶ Regional infusions (requires infusion pump)
 - ◊ Epidural: easy to place, requires large volumes and an externalized catheter; for infusions of opioids, local anesthetics, clonidine, useful for acute post-operative pain
 - ◊ Intrathecal: easy to internalize to implanted pump; for infusions of opioids, local anesthetics, clonidine, and ziconotide
 - ◊ Regional plexus: for infusions of local anesthetics, to anesthetize single extremity
 - ▶ Percutaneous vertebroplasty/kyphoplasty
 - ▶ Neurodestructive procedures for well-localized pain syndromes (spinal analgesics are used more frequently)
 - ◊ Head and neck: peripheral nerve block
 - ◊ Upper extremity: brachial plexus neurolysis
 - ◊ Thoracic wall: epidural neurolysis, intercostal neurolysis
 - ◊ Upper abdominal pain (visceral): celiac plexus block, thoracic splanchnicectomy
 - ◊ Midline pelvic pain: superior hypogastric plexus block
 - ◊ Rectal pain: intrathecal neurolysis, midline myelotomy or superior hypogastric plexus block
 - ◊ Unilateral pain syndromes: cordotomy
 - ◊ Consider intrathecal L/S phenol block
 - ▶ Neurostimulation procedures for cancer-related symptoms (ie, peripheral neuropathy)
 - ▶ Radiofrequency ablation for bone lesions

Interventional approaches are appropriate

- Nerve blocks
- Neuroaxial analgesia
- Percutaneous vertebroplasty/kyphoplasty
- Neuroablative
- Neurostimulation

Evaluate which pain site can be relieved; Will interventional technique provide tangible benefit?

Yes →
No →

Assess results of interventional technique

Reassess therapeutic plan interventional approaches not indicated at this time

Interventional approaches are not appropriate¹

Reassess therapeutic plan interventional approaches not indicated at this time

¹Infection, coagulopathy, very short or lengthy life expectancy, distorted anatomy, patient unwillingness, medications that increase risk for bleeding (eg, anti-angiogenesis agents such as bevacizumab) or technical expertise is not available.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

Discussion

This discussion is being updated to correspond with the newly updated algorithm. Last updated 05/06/08

NCCN Categories of Evidence and Consensus

Category 1: The recommendation is based on high-level evidence (e.g. randomized controlled trials) and there is uniform NCCN consensus.

Category 2A: The recommendation is based on lower-level evidence and there is uniform NCCN consensus.

Category 2B: The recommendation is based on lower-level evidence and there is nonuniform NCCN consensus (but no major disagreement).

Category 3: The recommendation is based on any level of evidence but reflects major disagreement.

All recommendations are category 2A unless otherwise noted.

Overview

Pain is one of the most common symptoms associated with cancer. Pain is defined as “a sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage.”¹ Cancer pain or cancer-related pain distinguishes pain experienced by cancer patients from that experienced by patients without malignancies. Pain occurs in approximately one quarter of patients with newly diagnosed malignancies, one third of patients undergoing treatment, and three quarters of patients with advanced disease.²⁻⁴ In addition, this is one of the symptoms patients fear most. Unrelieved pain denies them comfort and greatly affects their activities, motivation, interactions with family and friends, and overall quality of life.

The importance of relieving pain and the availability of effective therapies make it imperative that physicians and nurses caring for these patients be adept at the assessment and treatment of cancer pain.⁵⁻⁷ This requires familiarity with the pathogenesis of cancer pain; pain assessment techniques; common barriers to the delivery of appropriate analgesia; and pertinent pharmacologic, anesthetic, neurosurgical, and behavioral approaches to the treatment of cancer pain.

The most widely accepted algorithm for the treatment of cancer pain was developed by the World Health Organization (WHO).^{8,9} It suggests that patients with pain be started on acetaminophen or a nonsteroidal anti-inflammatory drug (NSAID). If this is not sufficient, the patient should be escalated to a “weak opioid,” such as codeine, and subsequently to a “strong opioid,” such as morphine. Although this algorithm has served as an excellent teaching tool, the management of cancer pain is considerably more complex than this three-tiered “cancer pain ladder” suggests.

This clinical practice guideline, developed by the National Comprehensive Cancer Network (NCCN) Adult Cancer Pain panel, is unique in several important ways. First, it contains several required components:

- Pain intensity must be quantified, as the algorithm bases therapeutic decisions on a numerical value assigned to the severity of the pain;
- A formal comprehensive pain assessment must be performed;
- Reassessment of pain intensity must be performed at specified intervals to ensure that the therapy selected is having the desired effect;
- Psychosocial support must be available; and
- Specific educational material must be provided to the patient.

Second, the guidelines acknowledge the range of complex decisions faced in caring for these patients. As a result, they provide dosing guidelines for nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, and co-analgesics. They also provide specific suggestions for the escalation of opioid dosage, management of opioid adverse effects, and when and how to proceed to other techniques for the management of cancer pain.

Pathophysiologic Classification

Different types of pain occur in cancer patients. A number of attempts have been made to classify pain according to different criteria. Pain classification includes differentiating between pain associated with tumor, pain associated with treatment, and pain unrelated to either. Acute and chronic pain should also be distinguished from each other when deciding what therapy to use. Therapeutic strategy depends on the pain pathophysiology, which is determined by patient examination and evaluation. There are two predominant mechanisms of pain pathophysiology: nociceptive and neuropathic.^{10,11}

Nociceptive pain is the result of injury to somatic and visceral structures and the resulting activation of nociceptors. Nociceptors are present in skin, viscera, muscles, and connective tissues. Nociceptive pain can further be divided into somatic pain and visceral pain.¹² Pain described as sharp, well localized, throbbing, and pressure-like is somatic nociceptive pain. It occurs often after surgical procedures or from bone metastasis. Visceral nociceptive pain is often described as more diffuse, aching, and cramping. It is secondary to compression, infiltration, or distension of abdominal thoracic viscera.

Neuropathic pain results from injury to the peripheral or central nervous system. This type of pain might be described as burning, sharp, or shooting. Examples of neuropathic pain include pain due to spinal

stenosis or diabetic neuropathy, or as an adverse effect of chemotherapy (eg, vincristine) or radiation therapy.

Comprehensive Pain Assessment

A comprehensive evaluation is essential to ensure proper pain management. Failure to adequately assess pain frequently leads to poor pain control. This algorithm begins with the premise that all patients with cancer should be screened for pain during the initial evaluation, at regular follow-up intervals, and whenever new therapy is initiated.

If pain is present on a screening evaluation the pain intensity must be quantified. Since pain is inherently subjective, patient's self-report to pain is the current standard of care for assessment. Intensity of pain should be quantified using a 0-10 numerical rating scale, a categorical scale, or a pictorial scale (e.g., The Faces Pain Rating Scale).¹³⁻¹⁵ The Faces Pain Rating Scale may be successful with patients who have difficulty with other scales, for example, children, the elderly, and patients with language or cultural differences or other communication barriers. If the patient is non-verbal an alternative method to obtain pain rating and pain assessment is used.

In addition to pain intensity, the patient should be asked to describe the characteristics of their pain (i.e., aching, burning etc.). If the patient has no pain, re-screening should be performed at each subsequent visit or as requested. Identifying the presence of pain through repeated screening is essential to allow implementation of effective pain management.

If the Pain Rating Scale score is above 0, a comprehensive pain assessment is initiated. The comprehensive pain assessment should focus on the type and quality of pain, pain history (such as onset, duration, course, etc.), pain intensity (i.e., pain experienced at rest; with movement; interference with activities); location, referral pattern,

radiation of pain; the associated factors that exacerbate or relieve the pain, current pain management plan; patient's response to current therapy; prior pain therapies; important psychosocial factors (such as patient distress, family and other support, psychiatric history, risk factors for aberrant use of pain medication, risk factors for undertreatment of pain, etc); other special issues relating to pain (such as meaning of pain for patient and family, cultural beliefs toward pain, spiritual or religious considerations). Finally, the patient's goals and expectations of pain management should be discussed, including level of comfort and function.

In addition, a thorough physical examination and review of appropriate laboratory and imaging studies are essential for a comprehensive pain assessment. This evaluation should enable caregivers to determine if the pain is related to an underlying cause that requires specific therapy. For example, it is inappropriate to provide only opioids to a patient suffering pain from impending spinal cord compression. Without glucocorticoids and local radiation therapy, the pain is unlikely to be well controlled, and the patient will remain at high risk for spinal cord injury.

The endpoint of comprehensive pain assessment is to diagnose the etiology and pathophysiology (somatic, visceral, or neuropathic) of the pain and individualize pain treatment plan based on mutually developed goals.

Management of Pain

For management of cancer related pain in adults, the algorithm distinguishes three levels of pain intensity, based on a 0-10 numerical rating scale (with 10 being the worst pain): severe pain (7-10); moderate pain (4-6); and mild pain (1-3).^{12,13}

It is important to separate pain related to an oncologic emergency from pain not related to an oncologic emergency (such as pain due bone

fracture or impending fracture of weight bearing bone; brain, epidural, or leptomeningeal metastases; pain related to infection; obstructed or perforated viscus).

In addition, the algorithm distinguishes pain not related to oncologic emergencies in patients not taking opioids from patients who have previously or are currently taking opioids for cancer pain, and also anticipated procedure related pain and anxiety.

Management of pain not related to an oncologic emergency in patients not taking opioids

Patients not taking opioids experiencing severe (i.e. pain intensity rating 7-10) should receive rapid titration of short-acting opioids, along with a bowel regimen, and nonopioid analgesics as indicated. Care providers should also provide psychosocial support and begin educational activities. Psychosocial support is needed to ensure that patients encountering common barriers to appropriate pain control (e.g., fear of addiction or side effects, inability to purchase opioids) or needing assistance in managing additional problems (e.g., depression, rapidly declining functional status) receive appropriate aid. The patient and the family must be educated regarding pain management and issues related to it. An individual approach should be used to determine opioid starting dose, frequency, and titration in order to achieve a balance between pain relief and medication adverse effects. Details of prophylactic bowel regimens and antiemetics are provided; management of these common opioid adverse effects should be started simultaneously with initiation of opioid therapy. Opioid-induced bowel dysfunction should be anticipated and treated prophylactically with a stimulating laxative to increase bowel motility, with or without stool softeners as indicated.¹⁶ Although pain intensity ratings will be obtained frequently to judge opioid dose increases, a formal re-evaluation is mandated within 24 hours for severe pain. If the pain at this time is unchanged or increased, the working diagnosis must be re-evaluated. In addition, the adequacy of opioid titration must be

re-evaluated by calculating and comparing the total parenteral morphine equivalents administered each day.

For patients not taking opioids, whose pain intensity rating is less than 7 (i.e. 4-6) at presentation, the pathways are quite similar to those for pain intensity 7-10 (above). The main differences include treatment beginning with slower titration of short-acting opioids and the option to perform the formal pain intensity re-evaluation less frequently (within 24-48 hours)

Patients not taking opioids and experiencing mild pain intensity (1-3) should receive treatment with NSAID or acetaminophen or treatment with slower titration of short-acting opioids. Re-evaluation of pain should be performed at each visit or as needed.

Addition of co-analgesic for specific pain syndromes should be considered for all groups of patients. Co-analgesics are drugs used to enhance the effects of opioids or NSAIDs.¹⁷ Also, optimize nonpharmacologic interventions. Co-analgesics belong to diverse classes of drugs and are commonly used to help manage bone pain, neuropathic pain, visceral pain and to reduce systemic opioid requirement. Acetaminophen,¹⁸ NSAIDs including selective COX-2 inhibitors, tricyclic anti-depressants (TCA), anti-convulsant drugs, bisphosphonates, and hormonal therapy are among the most commonly used medications. The NSAID and acetaminophen prescribing guidelines are presented on page PAIN-K. History of peptic ulcer disease, advanced age (>60 years old), male gender, and concurrent corticosteroid therapy should be considered before NSAIDs administration to prevent upper gastrointestinal tract bleeding and perforation. Well-tolerated proton pump inhibitors are recommended to prevent gastrointestinal side-effects induced by NSAIDs. NSAIDs should be prescribed with caution in patients older than 60 years of age or in those having compromised fluid status, renal insufficiency,

concomitant administration of other nephrotoxic drugs, and renally excreted chemotherapy in order to prevent renal toxicities.

Selecting an Appropriate Opioid and Route of Administration

While starting therapy, attempts should be made to determine the underlying pain mechanism and diagnose the pain syndrome. Optimal analgesic selection will depend on the patient's pain intensity, any current analgesic therapy, and concomitant medical illness(es). Morphine, hydromorphone, fentanyl, oxycodone are the opioids commonly used in the United States. If opioid adverse effects are significant, an improved balance between analgesia and adverse effects might be achieved by changing to an equivalent dose of an alternative opioid. This approach, known as opioid rotation, is now a widely accepted technique used to address poorly responsive pain.¹⁹ Relative effectiveness is important to consider when switching between oral and parenteral routes to avoid subsequent overdosing or underdosing. Equianalgesic dose ratios, opioid titration and maintenance are shown in the algorithm. For example, the morphine/hydromorphone ratio is about 6 for parenteral dose administration (60 mg of morphine equal to 10 mg of hydromorphone), which should be considered during opioid rotation.

Individual variations in methadone pharmacokinetics (long half-life ranging from 8 to more than 120 hours) make its usage very difficult in cancer patients.²⁰ Because of its long half-life, high potency, and inter-individual variations in pharmacokinetics, methadone should be started at lower-than-anticipated doses and slowly titrated upwards with provision of adequate short-acting breakthrough pain medications during the titration period. Consultation with a pain management specialist should be considered before its application.

Propoxyphene, meperidine, mixed agonist-antagonists, partial agonists, and placebos are not recommended for cancer patients. Meperidine and propoxyphene are especially contraindicated in patients with

impaired renal function or dehydration, because accumulation of renally-cleared metabolites may result in neurotoxicity or cardiac arrhythmias.²¹ Pure agonists (such as codeine, oxycodone, oxymorphone and fentanyl) are the most commonly used medications in the management of cancer pain. The short half-life opioid agonists (morphine, hydromorphone, fentanyl, and oxycodone) are preferred, because they can be more easily titrated than the long half-life analgesics (methadone and levorphanol).²²

The following methods of ongoing analgesic administration are widely used in clinical practice: “around the clock”, “as needed”, and “patient-controlled analgesia”. “Around the clock” dosing is provided to chronic pain patients for continuous pain relief. A “rescue dose” should be provided as a subsequent treatment for patients receiving these controlled-release medications. Rescue doses of short-acting opioids should be provided for pain that is not relieved by sustained/controlled release opioids. Opioids administered on an “as needed” basis are for patients who have intermittent pain with pain-free intervals. The “as needed” method is also used when rapid dose escalation is required. The patient-controlled analgesia (PCA) technique allows a patient to control a device that delivers a bolus of analgesic “on demand” (according to and limited by parameters set by a physician).

The least invasive, easiest, and safest route of opioid administration should be provided to ensure adequate analgesia. Oral is the preferred route of administration for chronic opioid therapy.²²⁻²⁴ The oral route should be considered first in patients who can take oral medications unless a rapid onset of analgesia is required or the patient experiences side-effects associated with the oral administration. Continuous parenteral infusion, intravenous (IV) or subcutaneous (SC), is recommended for patients who cannot swallow or absorb opioids enterally.

Initial oral dosage of opioids for patients with pain rating greater than or equal to 4 or for pain crisis depends on prior administration of opioids. An initial oral dose of 5-15 mg of morphine sulfate or equivalent is recommended for patients not already taking opioids. For patients currently on opioid therapy, the previous 24-hour dose and breakthrough dose (10%-20% of 24-hour dose) should be calculated and administered. Reassessment of efficacy and side-effects should be performed every 60 minutes to determine subsequent dose. Upon reassessment, if the pain score remains unchanged or is increased, opioid dose is increased by 50%-100%. If inadequate response is seen after 2-3 cycles of 50%-100% increased opioid dose, intravenous (IV) titration can be considered or a comprehensive pain assessment is carried out. If the pain score decreases to 4-6, the same dose of opioid is repeated and reassessment is performed at 60 minutes. If the pain score decreases to 0-3, the current effective dose of opioid is administered as per need and subsequent reassessment is performed in 2-3 hours to determine effective dose.

Initial intravenous loading dose of opioids for patients with pain rating greater than or equal to 4 or for pain crisis also depends on prior administration of opioids. The dose of 2-5 mg of intravenous morphine sulfate or equivalent is recommended for patients not taking opioids. For patients currently taking opioids, a dose increase of 10% of daily intravenous morphine equivalent is recommended. Reassessment of efficacy and side-effects should be performed every 15 minutes to calculate the subsequent dose of opioids. The subsequent dose of opioids for intravenous administration depends on the pain score after 15-minute reassessment. Upon reassessment if the pain score remains unchanged or is increased, the opioid dose is increased by 50%-100%. If inadequate response is seen after 2-3 cycles, alternate strategies can be considered or comprehensive pain assessment is carried out. If the pain score decreases to 4-6, the same dose of opioid is repeated and reassessment is performed at 15 minutes. If the pain

score decreases to 0-3, the current effective dose of opioid is administered as per need and subsequent reassessment is performed in 2-3 hours to determine effective dose.

After the initial response and treatment of uncontrolled pain, the patient should have a comprehensive reassessment. If an acceptable level of comfort and function has not been achieved for the patient, the NCCN Adult Cancer Pain panel recommends possible conversion to sustained-release medication with breakthrough dosing, nonopioid analgesics, management of side-effects, interventional procedures, and psychosocial and educational interventions. The subsequent treatment is based upon the patient's continued pain rating score.

Subsequent follow-up is recommended if the patient goals/expectations are achieved or for patients with mild (1-3) pain after comprehensive reassessment of the initial pharmacologic management. Routine follow-up should be done during each outpatient contact or at least each day for inpatients depending on patient conditions and institutional standards. Patients should be provided with a written follow-up plan and instructed on the importance of adhering to the medication plan, maintaining clinic appointments, and following-up with clinicians.

Management of Procedure-Related Pain and Anxiety

Procedure-related pain represents an acute short-lived experience which may be accompanied by a great deal of anxiety. Procedures reported as painful include bone marrow aspirations; lumbar puncture; skin and bone marrow biopsies; intravenous, arterial line, and central line injections. Much of the data available on procedure-related pain come from studies on pediatric patients with cancer which are then extrapolated to adults. Interventions to manage procedure-related pain should take into account the type of procedure, the anticipated level of pain, other individual characteristics of the patients such as age, and physical condition. The interventions may be multi-modal and may include pharmacological and/or nonpharmacological approaches. Local

anesthetics can be used to manage procedure-related pain with sufficient time for effectiveness as per package insert. Examples of local anesthetics include lidocaine, prilocaine, and tetracaine. Physical approaches such as cutaneous warming, laser or jet injection, and ultrasound may accelerate the onset of cutaneous anesthesia. Sedatives may also be used. However, deep sedation and general anesthesia must be carried out only by trained professionals.

Patients usually tolerate procedures better when they know what to expect. Therefore, patients and family members should receive written instructions for managing the pain.

Interventional Strategies

Some patients experience inadequate pain control despite pharmacological therapy or may not tolerate an opioid titration program because of side effects. Some patients may prefer procedural options instead of a chronic medication regimen. Several interventional strategies are available if a patient does not achieve adequate analgesia. Regional infusion of analgesics (epidural, intrathecal, and regional plexus), neuroablative procedures for well-localized pain syndromes (e.g., back pain due to facet or sacro-iliac joint arthropathy; visceral pain due to abdominal or pelvic malignancy), and neurostimulation procedures (i.e., for peripheral neuropathy) have proven successful in pain management. These techniques have been demonstrated in some cases, to eliminate or significantly reduce the level of pain, and/or may allow a significant decrease in systemic analgesics. The intrathecal route of opioid administration should be considered in patients with intolerable sedation, confusion, and/or inadequate pain control with systemic opioid administration. This approach is a valuable tool to improve analgesia for patients who have pain from a variety of anatomical locations (e.g., head and neck, upper and lower extremities, trunk).²⁵

Additional Therapies

Additional strategies specific to the pain situations can be considered. Specific recommendations for inflammatory pain, bone pain, nerve compression or inflammation, neuropathic pain, and pain likely to respond to antineoplastic therapies are provided. Overall, neuropathic pain is less responsive to opioids than pain caused by other pathophysiologies.

Other therapies, including specific non-traditional analgesic drugs, are usually indicated for neuropathic pain syndrome.²⁶ For example, a patient with neuropathic pain who failed to gain sufficient relief from opioids would be given a trial of an anticonvulsant or tricyclic antidepressant, whereas a patient with pancreatic cancer who was not tolerating opioids or not receiving adequate analgesia would be offered a celiac plexus block.


Nonpharmacologic specialty consultations for physical modalities (e.g., massage, physical therapy) and cognitive modalities (e.g., hypnosis, relaxation) may provide extremely beneficial adjuncts to pharmacologic interventions.

Attention should also be focused on psychosocial support, providing education to patients and families, and reducing the side effects of the opioid analgesics. Adverse effects such as constipation; nausea; sedation; Pruritus; myoclonus, and motor and cognitive impairment in cancer patients are fairly common, especially when multiple agents are used.²⁷⁻²⁹ Each adverse side effect requires a careful assessment and treatment. Proper management is necessary to prevent and reduce analgesic adverse effects.³⁰⁻³⁵ In addition, continued pain ratings should be obtained and documented in the medical record to ensure that the patient's pain remains under good control and goals of treatment are achieved. In addition, specialty consultations can be helpful in providing interventions to assist with difficult cancer pain problems. The major indication for referral to a specialty service

provider is if the pain is likely to be relieved or will help patients become functional in their daily activities. These modalities are delivered by a specialty service provider and pain management is accomplished by establishing individualized goals, then providing specific treatment and education for patients. The specialties include physical/occupational therapy, psychosocial supportive services, or interventional modalities.

Summary

In most patients, cancer pain can be successfully controlled with appropriate techniques and safe drugs. The overall approach to pain management encompassed in these guidelines is comprehensive. It is based on routine pain assessments, utilizes both pharmacologic and nonpharmacologic interventions, and requires ongoing reevaluation of the patient. The NCCN Adult Cancer Pain Practice Guidelines Panel advises that cancer pain can be well controlled in the vast majority of patients if the algorithms presented are systematically applied, carefully monitored, and tailored to the needs of the individual patient.



Recommended readings:

Kochhar R, Legrand SB, Walsh D et al. Opioids in cancer pain: Common dosing errors. *Oncology (Williston Park)* 2003; 17(4):571-579.

Ripamonti C, Zecca E, Bruera E. An update on the clinical use of methadone for cancer pain. *Pain* 1997; 70(2-3):109-115.



Discussion
update in
progress

References

1. Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy. Pain Suppl 1986; 3:S1-226.
2. Cohen MZ, Easley MK, Ellis C et al. Cancer pain management and the JCAHO's pain standards: an institutional challenge. J Pain Symptom Manage 2003; 25:519-527.
3. Goudas LC, Bloch R, Gialeli-Goudas M et al. The epidemiology of cancer pain. Cancer Invest 2005; 23:182-190.
4. Svendsen KB, Andersen S, Arnason S et al. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 2005; 9:195-206.
5. Cleeland CS, Gonin R, Hatfield AK et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994;330:592-596.
6. Martin LA, Hagen NA. Neuropathic pain in cancer patients: Mechanisms, syndromes, and clinical controversies. J Pain Symptom Manage 1997;14:99-117.
7. Mercadante S. Malignant bone pain: Pathophysiology and treatment. Pain 1997;69:1-18.
8. Stjernsward J. WHO cancer pain relief programme. Cancer Surv 1988;7:195-208.
9. Stjernsward J, Colleau SM, Ventafridda V. The World Health Organization Cancer Pain and Palliative Care Program: Past, present, and future. J Pain Symptom Manage 1996;12:65-72.
10. Hewitt DJ. The management of pain in the oncology patient. Obstetrics and Gynecology clinics of North America 2001;28:819-846.
11. Caraceni A, Weinstein SM. Classification of cancer pain syndromes. Oncology 2001;15:1627-1640.
12. Portenoy RK. Cancer pain: epidemiology and syndromes. Cancer 1989;63(suppl):2298-2307.
13. Serlin RC, Mendoza TR, Nakamura Y et al. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995;61:277-284.
14. Soetenga D, Frank J, Pellino TA. Assessment of the validity and reliability of the University of Wisconsin Children's Hospital Pain scale for Preverbal and Nonverbal Children. Pediatr Nurs 1999;25:670-676.
15. Hicks CL, von Baeyer CL, Spafford P et al., The faces pain scale-Revised: toward a common metric in pediatric pain measurement. Pain 2001;93:173-183.
16. American Pain Society. Principles of Analgesic use in the treatment of acute pain and cancer pain. 5th ed. Glenview, IL. American Pain Society; 2003.
17. Mercadante SL, Berchovich M, Casuccio A, Fulfaro F, Mangione S. A prospective randomized study of corticosteroids as adjuvant drugs to opioids in advanced cancer patients.
18. Stockler M, Vardy J, Pillai A, Warr D: Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial. J.Clin.Oncol. 2004; 22: 3389-3394.
19. McNicol E, Horowicz-Mehler N, Fisk RA et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain 2003;4:231-256.
20. Davis MP, Walsh D. Methadone for relief of cancer pain a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer. 2001;9:73-83.
21. Bruera E, Kim HN. Cancer pain. JAMA 2003;290(18):2476-2479.
22. Cherny NI. The pharmacologic management of cancer pain. Oncology (Williston Park) 2004;18:1499-1515.

23. Stevens RA, Ghazi SM. Routes of opioid analgesic therapy in the management of cancer pain. *Cancer Control* 2000;7:132-141.
24. Portenoy RK, Lesage P. Management of cancer pain. *Lancet* 1999;353:1695-1700.
25. Panchal SJ. Intrathecal Pumps. *Techniques in Regional Anesthesia and Pain Management* 2000;4:137-142.
26. Chen H, Lamer TJ, Rho RH et al. Contemporary management of neuropathic pain for the primary care physician. *Mayo Clin Proc.*2004;79:1533-1545.
27. Moryl N, Carver A, Foley KM. Pain and palliation. In: Holland JF, Frei E, eds. *Cancer Medicine*. 7th ed. Hamilton, ON: BC Decker Inc; 2006:1113-1124.
28. Wilson RK, Weissman DE. Neuroexcitatory effects of opioids: patient assessment #57. *J Palliat Med.* 2004;7:579.
29. Mercadante S. Pathophysiology and treatment of opioid-related myoclonus in cancer patients. *Pain.* 1998;74:5-9.
30. Reissig JE, Rybarczyk AM. Pharmacologic treatment of opioid-induced sedation in chronic pain. *Ann Pharmacother.* 2005;39:727-731.
31. Prommer E. Modafinil: is it ready for prime time? *J Opioid Manag.* 2006;2:130-136.
32. Katcher J, Walsh D. Opioid-induced itching: morphine sulfate and hydromorphone hydrochloride. *J Pain Symptom Manage.* 1999;17:70-72.
33. Tarcatu D, Tamasdan C, Moryl N, Obbens E. Are we still scratching the surface? A case of intractable pruritus following systemic opioid analgesia. *J Opioid Manag.* 2007;3:167-170.
34. Bruera E, Belzile M, Neumann C, Harsanyi Z, Babul N, Darke A. A doubleblind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. *J Pain Symptom Manage.* 2000;19:427-435.
35. Boettger S, Breitbart W. Atypical antipsychotics in the management of delirium: a review of the empirical literature. *Palliat Support Care.* 2005;3:227-237.

Discussion
update in
progress